Recommanded Product: tert-Butyl (5-aminopentyl)carbamateIn 2021 ,《First orally bioavailable prodrug of proteolysis targeting chimera (PROTAC) degrades cyclin-dependent kinases 2/4/6 in vivo》 was published in European Journal of Medicinal Chemistry. The article was written by Wei, Mingming; Zhao, Rui; Cao, Yuting; Wei, Yujiao; Li, Ming; Dong, Zhiqiang; Liu, Yulin; Ruan, Hao; Li, Ying; Cao, Sheng; Tang, Zhiwen; Zhou, Yuanyuan; Song, Wei; Wang, Yubo; Wang, Jiefu; Yang, Guang; Yang, Cheng. The article contains the following contents:
A growing number of reports suggested that the inhibitor targeting cyclin-dependent kinases (CDK) 2/4/6 can act as a more feasible chemotherapy strategy. In the present paper, a novel PROTAC mol. was developed based on the structure of Ribociclib′s derivative In malignant melanoma cells, the degrader can not only degrade CDK 2/4/6 simultaneously and effectively, but also remarkably induce cell cycle arrest and apoptosis of melanoma cells. Moreover, PROTAC mols. with CRBN ligands always have poor oral bioavailability. We developed the orally bioavailable prodrug for the first time. It would provide general solution for oral administration of the PROTAC mols., derived from CRBN ligands, for animal test conveniently. In the experiment, the researchers used many compounds, for example, tert-Butyl (5-aminopentyl)carbamate(cas: 51644-96-3Recommanded Product: tert-Butyl (5-aminopentyl)carbamate)
Some of the reported applications of tert-Butyl (5-aminopentyl)carbamate(cas: 51644-96-3) include: synthesis of of a supermacrocycle that self-assemble to form organic nanotubes., preparation of water-soluble unsymmetrical sulforhodamine fluorophores from monobrominated sulfoxanthene dye, synthesis of functionalized porphyrins as biocompatible carrier system for photodynamic therapy (PDT).Recommanded Product: tert-Butyl (5-aminopentyl)carbamate
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics